The UK is in an excellent position to establish a world-leading position in the field of data-driven health. Technologies such as machine learning, computer vision, and neural networks will accelerate drug discovery by measuring and characterising target engagement, validating targets in translatable cell models, improving our understanding of drugs, disease and drug-target interactions within patients. Advanced data science is also transforming medical imaging and other research techniques by using computing power to interpret data.
It is well known that health startups require strong ecosystems to accelerate their progress and increase success rates.
These eco-systems concentrate resources and bring them to bear on promising early stage ventures. The first and most prominent startup eco-system was Silicon Valley. The region successfully proved the model by clustering great minds from Stanford and other universities with capital from the Venture Capitalists (VCs) in Sandhill Road, a large flagship corporate, in Hewlett Packard and a dynamic community of entrepreneurial founders. This Silicon Valley model has been adopted by cities and regions across the globe as a benchmark for startup success.
During the last couple of decades European countries have developed their own Silicon Valley style ecosystems, usually clustered around cities. London’s Techcity has established a prominent position in Europe, ahead of cities such as Berlin, Stockholm and Barcelona. However, deep tech startups such as data-driven health and life science startups have specific requirements to enable them to flourish:
We have recognised an opportunity to bring together these various elements in London’s Knowledge Quarter, based around Kings Cross. We believe that the concentration of relevant capabilities represented by organisations such as The Francis Crick and Alan Turing Institutes, The Wellcome Trust, Google Deepmind and Benevolent.ai bring a huge potential opportunity to bring powerful resources to student entrepreneurs emerging from the London Universities who will create health startups. The excellent transport links provide strong connectivity to Cambridge and the rest of the UK.
This article is from a series contributed by the UK drug discovery community. For more information read our disclaimer.
Paul Dowling is the Lead for KQ Labs – an initiative launched by The Francis Crick Institute with funding from Innovate UK and support from Genomics England, HDRUK, Central Saint Martins, The Alan Turing Institute and The Knowledge Quarter. The programme is designed to support data-driven health startups with capital, workshops, mentoring and access to follow-on investment.
Preclinical to clinical, building a translational link between in vitro and in vivo models of neuroinflammation for drug discovery.